7-氟-3,3-二甲基-1,2-二氢吲哚 | 866208-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-氟-3,3-二甲基-1,2-二氢吲哚
• 英文名称: 7-fluoro-3,3-dimethylindoline
• 英文别名: 7-fluoro-3,3-dimethyl-1,2-dihydroindole
• CAS: 866208-25-5
• 化学式: C₁₀H₁₂FN
• 分子量: 165.21
• InChiKey: OVIBARJZPQQAGJ-UHFFFAOYSA-N

物化性质

• 沸点：
  224.4±39.0 °C(Predicted)
• 密度：
  1.051±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  7-氟-3,3-二甲基-1,2-二氢吲哚 在 4-二甲氨基吡啶 、 1,3-bis(4-methoxyphenyl)-4,5-dimethyl-1H-imidazol-3-ium chloride 、 三乙胺 、 cesium fluoride 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 5.0h， 生成 1,1,5-trimethyl-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one
  参考文献：
  名称：

  N-杂环卡宾催化带有α，β-不饱和酰胺的芳族氟化物的协同亲核芳香取代。

  摘要：

  协同的亲核芳族取代（CSN Ar）已经成为一种强大的机械流形，其中亲核芳族取代可以一步进行，而无需形成迈森海默中间体。然而，迄今为止报道的所有CSN Ar反应均需要化学计量的强碱或活化剂，并且尚未报道催化变体。在本文中，我们报告了通过CSN Ar反应，N杂环卡宾（NHC）催化的在氮原子上包含2-氟苯基的丙烯酰胺的分子内环化反应。通过使用这种催化方法，可以合成一系列喹啉-2-酮衍生物，它们是药物和有机材料中常见的结构基序。

  DOI：

  10.1002/anie.201907837
• 作为产物：
  描述：

  7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 在 红铝 、 sodium hydroxide 作用下， 以 甲苯 为溶剂， 反应 1.0h， 以93%的产率得到7-氟-3,3-二甲基-1,2-二氢吲哚
  参考文献：
  名称：

  1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as Potent and Selective Norepinephrine Reuptake Inhibitors

  摘要：

  Efforts to identify new selective and potent norepinephrine reuptake inhibitors (NRIs) For multiple indications by structural modification of the previous 3-(arylamino)-3-phenylpropan-2-olamine scaffold led to the discovery of it novel series of 1-(indolin-1-yl)-1-phenyl-3-propan-2-olamines (9). Investigation of the structure-activity relationships revealed that small alkyl substitution at the C3 position of the indoline ring enhanced selectivity for the norepinephrine transporter (NET) over the serotonin transporter (SERT). Several compounds bearing a 3,3-dimethyl group on the indoline ring, 9k, 9o,p, and 9s,t, exhibited potent inhibition of NET (IC(50) = 2.7-6.5 nM) and excellent selectivity over both serotonin and dopamine transporters. The best example from this series, 9p, a potent and highly selective NRI, displayed oral efficacy In a telemetric rat model of ovariectomized-induced thermoregulatory dysfunction, it mouse p-phenylquinone (PPQ) model of acute visceral pain, and a rat spinal nerve ligation (SNL) model of neuropathic pain.

  DOI：

  10.1021/jm901559e

文献信息

• Phenylaminopropanol derivatives and methods of their use
  申请人：Kim Younghee Callain

  公开号：US20050222148A1

  公开（公告）日：2005-10-06

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及式I的苯胺丙醇衍生物： 或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于通过单胺再摄取改善的症状的预防和治疗方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及其中的组合，特别是从包括重性抑郁障碍、血管运动症状、压力性和切勿性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合的一组中选择的那些症状。
• DIHYDROBENZOFURANYL DERIVATIVES AND METHODS OF THEIR USE
  申请人：Zhang Puwen

  公开号：US20080153873A1

  公开（公告）日：2008-06-26

  The present invention is directed to dihydrobenzofuranyl derivatives of formula I: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorder, cognitive disorder, diabetic neuropathy, pain, and other diseases or disorders.

  本发明涉及具有以下结构的二氢苯并呋喃基衍生物：或其药用盐，这些衍生物是单胺再摄取抑制剂，含有这些衍生物的组合物，以及它们用于预防和治疗条件的方法，包括但不限于血管运动症状性功能障碍、胃肠道紊乱和泌尿系统紊乱、抑郁症、内源性行为障碍、认知障碍、糖尿病性神经病变、疼痛和其他疾病或障碍。
• [EN] 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS)<br/>[FR] DERIVES DE 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZINE-1-YL)-1-PHENYLE PROPAN-2-OL ET COMPOSES ASSOCIES UTILISES EN TANT QUE MODULATEURS DE L'ACTIVITE DE LA NOREPINEPHRINE (NE) ET DE LA SEROTONINE (5-HT) ET REABSORPTION DE LA MONOAMINE DANS LE TRAITEMENT DES SYMPTOMES VASOMOTEURS
  申请人：WYETH CORP

  公开号：WO2005097744A1

  公开（公告）日：2005-10-20

  The present invention is directed to phenylaminopropanol derivatives of formula (I): or a pharmaceutically acceptable salt thereof; wherein: the dotted line between Y and Z represents an optional double bond; the dotted line between the two R4 groups represents an optional heterocyclic ring of 4 to 6 ring atoms that may be formed between the two R4 groups, together with the nitrogen through which they are attached; Y is N, CR6, or C=O; Z is N, CR7, CR5, or C(R5)2; R2 is aryl substituted with 0-3 R1 or heteroaryl substituted with 0-3 R1; R3 is H or C1-C4 alkyl; n is an integer form 0 to 4; x is an integer from 1 to 2; and the other substituents are defined in the claims; compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected form the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及公式（I）的苯基氨丙醇衍生物或其药学上可接受的盐;其中：Y和Z之间的虚线表示可选的双键;两个R4基团之间的虚线表示可选的4至6个环原子的杂环环，可以与它们连接的氮一起形成在两个R4基团之间; Y为N，CR6或C = O; Z为N，CR7，CR5或C（R5）2; R2为芳基，用0-3个R1取代或杂芳基，用0-3个R1取代; R3为H或C1-C4烷基; n为0至4的整数; x为1至2的整数;其他取代基在权利要求中定义; 包含这些衍生物的组合物，以及它们的使用方法，用于改善单胺再摄取所缓解的病症的预防和治疗，包括但不限于血管运动症状（VMS），性功能障碍，胃肠和泌尿系统疾病，慢性疲劳综合征，纤维肌痛综合征，神经系统疾病以及其组合，特别是选择自由基组成的条件，包括重度抑郁症，血管运动症状，压力和切望性尿失禁，纤维肌痛，疼痛，糖尿病神经病变以及其组合。
• Phenylaminopropanol Derivatives and Methods of Their Use
  申请人：Kim Callain Younghee

  公开号：US20090093469A1

  公开（公告）日：2009-04-09

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及公式I的苯基氨丙醇衍生物： 或其药学上可接受的盐，包含这些衍生物的组合物，以及它们的使用方法，用于预防和治疗通过单胺再摄取改善的疾病，包括但不限于血管运动症状（VMS），性功能障碍，胃肠和泌尿系统疾病，慢性疲劳综合症，纤维肌痛综合症，神经系统疾病和组合疾病，特别是从包括重度抑郁障碍，血管运动症状，压力和切欲性尿失禁，纤维肌痛，疼痛，糖尿病神经病变和组合疾病的组中选择的那些疾病。
• 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS)
  申请人：Wyeth

  公开号：EP1732887B1

  公开（公告）日：2008-01-09